Prevalence of baseline NS3 resistance-associated substitutions (RASs) on treatment with protease inhibitors in patients infected with HCV genotype 1
Copyright © 2019 Elsevier Masson SAS. All rights reserved..
BACKGROUND AND AIMS: Treatment for hepatitis C has evolved significantly with the licensing of direct-acting antiviral drugs (DAAs). However, one of the limiting factors of the effectiveness of antiviral therapy with protease inhibitors (PIs) is the emergence of resistance caused by point mutations. The aim of this study was to determine the prevalence of resistance-associated substitutions (RASs) in HCV NS3 gene in patients infected with genotype 1 before therapy with simeprevir.
METHODS: A total of 73 serum samples from 15 treatment-experienced patients with boceprevir/telaprevir and 58 DAA-naïve patients were collected before therapy with DAAs simeprevir, daclatasvir and/or sofosbuvir. Presence of baseline resistance-associated substitutions (RAS) in the serine protease domain of HCV NS3 was analyzed by nucleotide sequencing followed by amino acid deduction.
RESULTS: Overall RAS prevalence in this study was 13.7% (10/73). RAS prevalence for HCV subtype 1b was 17.4% (4/23) while for HCV subtype 1a was 12% (6/50). Primary mutations V36M/L and R155K were observed only in HCV subtype 1a, whereas T54S and Q80K were identified only in HCV subtype 1b. RAS V36M, which is related to reduction of susceptibility to second-generation PIs, was the most frequent in the study (6.9%; 5/73).
CONCLUSIONS: Our results indicated that Brazilian isolates of HCV present a distinct pattern of RAS depending on the infecting viral subtype. In contrast to data from other countries, RAS Q80K prevalence in Brazil is low in HCV subtype 1a. This study improves the knowledge of genetic barrier for resistance to PIs involving RASs in chronically infected patients and its possible impact on an unsuccessful treatment outcome, information that might be crucial to upcoming decisions of incorporation of new DAAs in Brazilian guidelines of antiviral therapy against HCV infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Clinics and research in hepatology and gastroenterology - 43(2019), 6 vom: 09. Nov., Seite 700-706 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Costa, Vanessa Duarte [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 15.10.2020 Date Revised 15.10.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clinre.2019.02.009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM295031077 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM295031077 | ||
| 003 | DE-627 | ||
| 005 | 20231225082755.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clinre.2019.02.009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0983.xml |
| 035 | |a (DE-627)NLM295031077 | ||
| 035 | |a (NLM)30880098 | ||
| 035 | |a (PII)S2210-7401(19)30048-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Costa, Vanessa Duarte |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prevalence of baseline NS3 resistance-associated substitutions (RASs) on treatment with protease inhibitors in patients infected with HCV genotype 1 |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.10.2020 | ||
| 500 | |a Date Revised 15.10.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a BACKGROUND AND AIMS: Treatment for hepatitis C has evolved significantly with the licensing of direct-acting antiviral drugs (DAAs). However, one of the limiting factors of the effectiveness of antiviral therapy with protease inhibitors (PIs) is the emergence of resistance caused by point mutations. The aim of this study was to determine the prevalence of resistance-associated substitutions (RASs) in HCV NS3 gene in patients infected with genotype 1 before therapy with simeprevir | ||
| 520 | |a METHODS: A total of 73 serum samples from 15 treatment-experienced patients with boceprevir/telaprevir and 58 DAA-naïve patients were collected before therapy with DAAs simeprevir, daclatasvir and/or sofosbuvir. Presence of baseline resistance-associated substitutions (RAS) in the serine protease domain of HCV NS3 was analyzed by nucleotide sequencing followed by amino acid deduction | ||
| 520 | |a RESULTS: Overall RAS prevalence in this study was 13.7% (10/73). RAS prevalence for HCV subtype 1b was 17.4% (4/23) while for HCV subtype 1a was 12% (6/50). Primary mutations V36M/L and R155K were observed only in HCV subtype 1a, whereas T54S and Q80K were identified only in HCV subtype 1b. RAS V36M, which is related to reduction of susceptibility to second-generation PIs, was the most frequent in the study (6.9%; 5/73) | ||
| 520 | |a CONCLUSIONS: Our results indicated that Brazilian isolates of HCV present a distinct pattern of RAS depending on the infecting viral subtype. In contrast to data from other countries, RAS Q80K prevalence in Brazil is low in HCV subtype 1a. This study improves the knowledge of genetic barrier for resistance to PIs involving RASs in chronically infected patients and its possible impact on an unsuccessful treatment outcome, information that might be crucial to upcoming decisions of incorporation of new DAAs in Brazilian guidelines of antiviral therapy against HCV infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a HCV | |
| 650 | 4 | |a Protease inhibitors | |
| 650 | 4 | |a RAS | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a NS3 protein, hepatitis C virus |2 NLM | |
| 650 | 7 | |a Protease Inhibitors |2 NLM | |
| 650 | 7 | |a Viral Nonstructural Proteins |2 NLM | |
| 700 | 1 | |a Delvaux, Nathália |e verfasserin |4 aut | |
| 700 | 1 | |a Brandão-Mello, Carlos Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Nunes, Estevão Portela |e verfasserin |4 aut | |
| 700 | 1 | |a de Sousa, Paulo Sérgio Fonseca |e verfasserin |4 aut | |
| 700 | 1 | |a de Souza Rodrigues, Lia Laura Lewis Ximenez |e verfasserin |4 aut | |
| 700 | 1 | |a Lampe, Elisabeth |e verfasserin |4 aut | |
| 700 | 1 | |a do Amaral Mello, Francisco Campello |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinics and research in hepatology and gastroenterology |d 2011 |g 43(2019), 6 vom: 09. Nov., Seite 700-706 |w (DE-627)NLM201280868 |x 2210-741X |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2019 |g number:6 |g day:09 |g month:11 |g pages:700-706 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clinre.2019.02.009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2019 |e 6 |b 09 |c 11 |h 700-706 | ||